IRTC Quote, Financials, Valuation and Earnings

AtriCure, Inc. has a net margin of -2.7% compared to iRhythm Holdings, Inc.'s net margin of 1.25%. iRhythm Holdings, Inc.'s return on equity of -54.18% beat AtriCure, Inc.'s return on equity of -2.44%.

iRhythm Holdings, Inc. has a consensus price target of $221.27, signalling upside risk potential of 39.27%. On the other hand AtriCure, Inc. has an analysts' consensus of $48.78 which suggests that it could grow by 50.64%. Given that AtriCure, Inc. has higher upside potential than iRhythm Holdings, Inc., analysts believe AtriCure, Inc. is more attractive than iRhythm Holdings, Inc..

iRhythm Holdings, Inc. has a beta of 1.062, which suggesting that the stock is 6.245% more volatile than S&P 500. In comparison AtriCure, Inc. has a beta of 1.415, suggesting its more volatile than the S&P 500 by 41.514%.

iRhythm Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AtriCure, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Holdings, Inc. pays -- of its earnings as a dividend. AtriCure, Inc. pays out -- of its earnings as a dividend.

iRhythm Holdings, Inc. quarterly revenues are $192.9M, which are larger than AtriCure, Inc. quarterly revenues of $140.5M. iRhythm Holdings, Inc.'s net income of -$5.2M is lower than AtriCure, Inc.'s net income of $1.8M. Notably, iRhythm Holdings, Inc.'s price-to-earnings ratio is -- while AtriCure, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Holdings, Inc. is 7.19x versus 2.89x for AtriCure, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Baxter International, Inc. has a net margin of -2.7% compared to iRhythm Holdings, Inc.'s net margin of -34.8%. iRhythm Holdings, Inc.'s return on equity of -54.18% beat Baxter International, Inc.'s return on equity of -12.97%.

iRhythm Holdings, Inc. has a consensus price target of $221.27, signalling upside risk potential of 39.27%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.63 which suggests that it could grow by 1.38%. Given that iRhythm Holdings, Inc. has higher upside potential than Baxter International, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than Baxter International, Inc..

iRhythm Holdings, Inc. has a beta of 1.062, which suggesting that the stock is 6.245% more volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.747%.

iRhythm Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.44% to investors and pays a quarterly dividend of $0.01 per share. iRhythm Holdings, Inc. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.

iRhythm Holdings, Inc. quarterly revenues are $192.9M, which are smaller than Baxter International, Inc. quarterly revenues of $3B. iRhythm Holdings, Inc.'s net income of -$5.2M is higher than Baxter International, Inc.'s net income of -$1B. Notably, iRhythm Holdings, Inc.'s price-to-earnings ratio is -- while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Holdings, Inc. is 7.19x versus 0.98x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integra LifeSciences Holdings Corp. has a net margin of -2.7% compared to iRhythm Holdings, Inc.'s net margin of -1.34%. iRhythm Holdings, Inc.'s return on equity of -54.18% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

iRhythm Holdings, Inc. has a consensus price target of $221.27, signalling upside risk potential of 39.27%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 28.63%. Given that iRhythm Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe iRhythm Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..

iRhythm Holdings, Inc. has a beta of 1.062, which suggesting that the stock is 6.245% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.036, suggesting its more volatile than the S&P 500 by 3.641%.

iRhythm Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Holdings, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

iRhythm Holdings, Inc. quarterly revenues are $192.9M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. iRhythm Holdings, Inc.'s net income of -$5.2M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, iRhythm Holdings, Inc.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Holdings, Inc. is 7.19x versus 0.56x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -2.7% compared to iRhythm Holdings, Inc.'s net margin of -8.49%. iRhythm Holdings, Inc.'s return on equity of -54.18% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.

iRhythm Holdings, Inc. has a consensus price target of $221.27, signalling upside risk potential of 39.27%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.91 which suggests that it could grow by 41.16%. Given that Tandem Diabetes Care, Inc. has higher upside potential than iRhythm Holdings, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than iRhythm Holdings, Inc..

iRhythm Holdings, Inc. has a beta of 1.062, which suggesting that the stock is 6.245% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.285%.

iRhythm Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Holdings, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

iRhythm Holdings, Inc. quarterly revenues are $192.9M, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. iRhythm Holdings, Inc.'s net income of -$5.2M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, iRhythm Holdings, Inc.'s price-to-earnings ratio is -- while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Holdings, Inc. is 7.19x versus 1.23x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.